Acadia Pharmaceuticals' CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand, expansion into rare disease marketing, and the role of AI in its strategy.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it expands into the rare disease space, with AI playing a major role in its marketing strategy.
- Rebranding to expand into rare disease space
- Using AI in marketing strategy
- Challenges and benefits of marketing as a smaller biotech
AI will play a major role in Acadia's marketing strategy under the new brand identity moving forward.
CEO Catherine Owen Adams draws on her marketing background to steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.